QIYU BIOTECH
Qi Xiangdong, founder of Qiyu Bio, said: “Innovation is the starting and future of Qiyu Bio, and it is the core driving force of enterprise development. Qiyu Bio will use the first-class antibody technology platform to build superior biopharmaceutical pipelines and explore the field of biotherapy. A big breakthrough. With the development and improvement of the company, Qiyu will have core competitiveness in more fields.
QIYU BIOTECH
Industry:
Biotechnology Health Care Medical
Founded:
2017-07-01
Address:
Shanghai, Shanghai, China
Country:
China
Total Employee:
11+
Status:
Active
Total Funding:
31.4 M USD
Similar Organizations
Cagen Bio
Cagen Bio is a vitro diagnostic reagents developer.
Dima Biotech
Dima Biotech is a cancer immunotherapy and monoclonal antibody developer.
Qihan Biotech
Qihan Biotech is a gene-editing organ transplantation technology developer.
Virogin Biotech
Virogin Biotech is an antineoplastic drug developer.
Yusu Biotech
Yusu Biotech is a hair care products developer.
Investors List
Tririver Capital
Tririver Capital investment in Series B - Qiyu Biotech
Oriza Prior
Oriza Prior investment in Series B - Qiyu Biotech
BOCOM International
BOCOM International investment in Series B - Qiyu Biotech
Shanghai Pudong Science and Technology Investment
Shanghai Pudong Science and Technology Investment investment in Series B - Qiyu Biotech
Longmen Capital
Longmen Capital investment in Series B - Qiyu Biotech
Watson Investment
Watson Investment investment in Series A - Qiyu Biotech
Jundu Investment
Jundu Investment investment in Series A - Qiyu Biotech
More informations about "Qiyu Biotech"
About QY - QY BIOTECH
Shenzhen Qiyu Biotechnology Co., Ltd. Shenzhen Qiyu Biotechnology Co., Ltd. was established in 2021 by a group of scientists who are committed to developing innovative products for the …See details»
Qiyu Biotech - Crunchbase Company Profile & Funding
9,256 Number of Organizations • $176.9B Total Funding Amount • 50,542 Number of Investors. Track . Asia Biotechnology Companies with Early Stage Venture Funding . ... Qiyu Biotech …See details»
Qiyu Biotech 2025 Company Profile: Valuation, Funding
Qiyu Biotech General Information Description. Developer of macromolecular biopharmaceutical drug designed to treat refractory cancers and autoimmune diseases. The company's platform …See details»
Beijing Qiyu Biotechnology Co., Ltd. - Drug pipelines, Patents ...
Explore Beijing Qiyu Biotechnology Co., Ltd. with its drug pipeline, therapeutic area, technology platform, . ... Explore the financial positions of over 360K organizations with Synapse. login. or. …See details»
Guangdong Qiyu Biotechnology Co., Ltd. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Guangdong Qiyu Biotechnology Co., Ltd. of Xinxing County, Guangdong. Get the latest business insights …See details»
Guangzhou Qiyu Biotechnology Co., Ltd - cnverify.com
Dec 25, 2014 location of Guangzhou Qiyu Biotechnology Co., Ltd Address Room 702, 7th Floor, Building 3, Greenland Huichuang Plaza, No. 6 Kexing Road, Guangzhou Private Science and …See details»
Qiyu Biotech - Web3 Crypto Company Profile, Funding, Valuation ...
Qiyu Biotech is an innovative macromolecular drug developer. 11 - 50 Highlights. Total Funding Amount. ¥200M. Funding Rounds. 2. Investors. 4. Details Last Funding Type Series A …See details»
Qiyu Biotech of Shanghai Completes A Funding Round …
Aug 14, 2019 Qiyu Biotechnology, a Shanghai startup located in Zhangjiang Hi-Tech Park, completed a Series A round that raised “tens of millions of RMB” from Jundu Investment and Wosheng Capital. This proceeds are earmarked to …See details»
Qiyu Biotech - Headquarter Location, Corporate Office Address …
Qiyu Biotech is Biotechnology in China that focus on developer business. They cover business area such as developer, macromolecular biopharmaceutical drug, refractory cancer, …See details»
Qiyu Biotech - Funding, Financials, Valuation & Investors
Qiyu Biotech is an innovative macromolecular drug developer. New. Resources. Advanced Search. Start Free Trial ... Experience the new Crunchbase, powered by AI . Experience the …See details»
Qiyu Bio Lands Tens of Millions of Yuan in Series A Financing
Qiyu Biotechnology（Qiyu Bio） has announced the completion of tens of millions yuan in series A financing, jointly invested by Jundu Investment and Wosheng Capital. This round of …See details»
Guangzhou Qiyu Biotechnology Co., Ltd. - Drug pipelines, Patents ...
Last update 19 Sep 2024. Guangzhou Qiyu Biotechnology Co., Ltd. Private Company |See details»
Hengrui Medicine's Apatinib and Qiyu Bio-Q-1802 announced a …
The product "Q-1802" is an innovative drug for the treatment of tumors developed by Qiyu Biotech. It is a double antibody that simultaneously targets Claudin 18.2 and PD-L1. Due o its …See details»
Qiyu Biotech - Crunchbase
Qiyu Biotech is an innovative macromolecular drug developer. Experience the new Crunchbase, powered by AISee details»
Career Development - QY BIOTECH
Talent Strategy Qiyu Bio- regards talents as an indispensable resource for the company’s development Oriented by the company’s strategic goals, Qiyu Biological has extensively …See details»
Huaian Qiyu Biotechnology Co., Ltd. - Drug pipelines, Patents, …
May 17, 2025 Last update 08 May 2025. Huaian Qiyu Biotechnology Co., Ltd. Dissolved | Private Company | 2020 | Jiangsu Sheng, ChinaSee details»
WO2023168758 - Drug Targets, Indications, Patents - Synapse
WO2023168758, Initially developed by Shenzhen Qiyu Biotechnology Co., Ltd., Now, its global highest R&D status is Discovery, Therapeutic Areas: Neoplasms,Infectious ...See details»
Series B - Qiyu Biotech - 2021-12-23 - Crunchbase
Organization Name . Qiyu Biotech . Announced Date Dec 23, 2021; Funding Type ...See details»
首页 - QY BIOTECH
Faustovirus 病毒加帽酶（FCE） FCE 加帽酶能够极大地提高 mRNA 加帽效率，特别适用于困难的转录模板。FCE 是一种单亚基酶，具有给 RNA 加 Cap-0 帽所需的三种酶活：三磷酸酶， …See details»
QureBio Biotechnology Completes Series A Financing
Shanghai, China - April 10, 2020, Qiyu Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as QureBio) recently announced the completion of tens of millions of a + rounds of financing, …See details»